drugset
drugset / Trial / NCT05215574

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574 ↗

Phase 1 Active not recruiting 130 enrolled NGM Biopharmaceuticals, Inc Merck Sharp & Dohme LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Timeline

Start
2022-03-31
Primary completion
2025-07
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject NGM438 Unknown — Intravenous
Subject NGM831 Unknown — Intravenous
Background Pembrolizumab Monoclonal antibody — Intravenous

Indications

bladder transitional cell carcinoma breast cancer cholangiocarcinoma colorectal carcinoma endocervical carcinoma esophageal cancer gastric cancer head and neck squamous cell carcinoma malignant pancreatic neoplasm melanoma mesothelioma non-small cell lung carcinoma ovarian cancer prostate cancer renal cell carcinoma